ADC Payload (ADC Cytotoxin)

Modified MMAF is an ADC cytotoxin that functions by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. It is primarily utilized in the synthesis of Antibody-drug Conjugates (ADCs), enhancing the specificity and efficacy of targeted cancer therapies. This compound is a valuable tool for research applications focused on cancer treatment modalities and the development of targeted drug delivery systems.

Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A.

alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting RNA-polymerase II.

Duocarmycin is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity. Duocarmycin is a DNA minor groove binding alkylating agent and explored as drug?Cantibody conjugates (ADCs) .

Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

PNU-159682, a highly potent metabolite of the anthracycline nemorubicin (DNA topoisomerase II inhibitor) with outstanding cytotoxicity, is a potent ADCs cytotoxin.

MMAF-Ome, an antitubulin agent, belongs to ADC.

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features.

Duocarmycin MA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-drug resistant cell lines.

Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.

N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic.

Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.

altobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin.

Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates. Auristatin F inhibits cell division by blocking the polymerisation of tubulin.

Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.

Dolastatin 10 (DLS 10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymerization.

Duocarmycin SA is a potent antitumor antibiotic with an IC50 of 10 pM.

DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody drug conjugate.

Duocarmycin MB is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MB can be used against multi-drug resistant cell lines.

C-11 is a tubulin inhibitor and acts as a ADC cytotoxin, displays cytotoxicity for carcinoma cell lines.

(+)-CBI-CDPI2 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI2 is an antibody drug conjugates (ADCs) toxin.

(+)-CBI-CDPI1 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI1 is an antibody drug conjugates (ADCs) toxin.

Duocarmycin GA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-drug resistant cell lines.

Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.

γ-Amanitin is a potent ADC cytotoxin derived from the Amanita mushroom, specifically targeting RNA polymerase II to inhibit mRNA synthesis. This compound exhibits high toxicity across various cell types, making it a valuable tool in cancer research and therapeutic applications. γ-Amanitin competes effectively with monoclonal antibodies, displaying an IC50 value of 163.1 ng/mL. Its ability to disrupt transcriptional processes positions it as a key reagent in studies focused on gene expression and cellular response mechanisms.

Mytoxin B is an ADC cytotoxin that functions as a satratoxin-type trichothecene macrolide. It is known for inducing cell apoptosis primarily through the PI3K/Akt signaling pathway. This compound is utilized in research applications focused on targeted cancer therapies and the study of apoptosis mechanisms in various cell types.

Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative designed for use as an antibody-drug conjugate (ADC) payload. This compound exhibits moderate DNA alkylating activity, contributing to its potent cytotoxic effects on target cells. It is primarily utilized in research applications focused on developing targeted cancer therapies through antigen-dependent cytotoxicity mechanisms.

(S,S)-D211 is a stereoisomer of D211 that functions as a potent ADC payload through its DNA-damaging activity. As a member of the PBD dimer family, (S,S)-D211 is designed for incorporation into antibody-drug conjugates (ADCs), enhancing their cytotoxic efficacy in targeted cancer therapies. Its ability to induce DNA damage makes it a valuable tool for research in the development of innovative cancer treatments.